INQUISUR   21779
INSTITUTO DE QUIMICA DEL SUR
Unidad Ejecutora - UE
artículos
Título:
Dinuclear Copper(II) complexes of Fenoprofen with nitrogenated ligands: synthesis, spectroscopic, thermal and SOD-mimic activity studies
Autor/es:
AGOTEGARAY, MARIELA; BOERIS, MÓNICA; DIEZ, ALEJANDRA; PRAT, MARÍA ROSA; QUINZANI, OSCAR
Revista:
JOURNAL OF COORDINATION CHEMISTRY
Editorial:
TAYLOR & FRANCIS LTD
Referencias:
Lugar: Londres; Año: 2011 vol. 64 p. 2246 - 2261
ISSN:
0095-8972
Resumen:
Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3-
phenoxyphenyl)propionic acid] and nitrogen donors of general formula [Cu2(fen)4(L)]n were
prepared from [Cu2(fen)4(dmf)2]2H2O (1) [dmf¼N,N0-dimethylformamide; L¼4,40-bipyridine
(2), pyrazine (3), and 2,5-dimethylpyrazine (4)]. The new complexes were characterized by
chemical analysis, spectroscopic, and thermogravimetric techniques. Antioxidant properties of
chemical analysis, spectroscopic, and thermogravimetric techniques. Antioxidant properties of
chemical analysis, spectroscopic, and thermogravimetric techniques. Antioxidant properties of
(2), pyrazine (3), and 2,5-dimethylpyrazine (4)]. The new complexes were characterized by
chemical analysis, spectroscopic, and thermogravimetric techniques. Antioxidant properties of
chemical analysis, spectroscopic, and thermogravimetric techniques. Antioxidant properties of
chemical analysis, spectroscopic, and thermogravimetric techniques. Antioxidant properties of
(2), pyrazine (3), and 2,5-dimethylpyrazine (4)]. The new complexes were characterized by
chemical analysis, spectroscopic, and thermogravimetric techniques. Antioxidant properties of
chemical analysis, spectroscopic, and thermogravimetric techniques. Antioxidant properties of
chemical analysis, spectroscopic, and thermogravimetric techniques. Antioxidant properties of
prepared from [Cu2(fen)4(dmf)2]2H2O (1) [dmf¼N,N0-dimethylformamide; L¼4,40-bipyridine
(2), pyrazine (3), and 2,5-dimethylpyrazine (4)]. The new complexes were characterized by
chemical analysis, spectroscopic, and thermogravimetric techniques. Antioxidant properties of
chemical analysis, spectroscopic, and thermogravimetric techniques. Antioxidant properties of
chemical analysis, spectroscopic, and thermogravimetric techniques. Antioxidant properties of
(2), pyrazine (3), and 2,5-dimethylpyrazine (4)]. The new complexes were characterized by
chemical analysis, spectroscopic, and thermogravimetric techniques. Antioxidant properties of
chemical analysis, spectroscopic, and thermogravimetric techniques. Antioxidant properties of
chemical analysis, spectroscopic, and thermogravimetric techniques. Antioxidant properties of
(2), pyrazine (3), and 2,5-dimethylpyrazine (4)]. The new complexes were characterized by
chemical analysis, spectroscopic, and thermogravimetric techniques. Antioxidant properties of
chemical analysis, spectroscopic, and thermogravimetric techniques. Antioxidant properties of
chemical analysis, spectroscopic, and thermogravimetric techniques. Antioxidant properties of
prepared from [Cu2(fen)4(dmf)2]2H2O (1) [dmf¼N,N0-dimethylformamide; L¼4,40-bipyridine
(2), pyrazine (3), and 2,5-dimethylpyrazine (4)]. The new complexes were characterized by
chemical analysis, spectroscopic, and thermogravimetric techniques. Antioxidant properties of
chemical analysis, spectroscopic, and thermogravimetric techniques. Antioxidant properties of
chemical analysis, spectroscopic, and thermogravimetric techniques. Antioxidant properties of
(2), pyrazine (3), and 2,5-dimethylpyrazine (4)]. The new complexes were characterized by
chemical analysis, spectroscopic, and thermogravimetric techniques. Antioxidant properties of
chemical analysis, spectroscopic, and thermogravimetric techniques. Antioxidant properties of
chemical analysis, spectroscopic, and thermogravimetric techniques. Antioxidant properties of
(2), pyrazine (3), and 2,5-dimethylpyrazine (4)]. The new complexes were characterized by
chemical analysis, spectroscopic, and thermogravimetric techniques. Antioxidant properties of
chemical analysis, spectroscopic, and thermogravimetric techniques. Antioxidant properties of
chemical analysis, spectroscopic, and thermogravimetric techniques. Antioxidant properties of
2(fen)4(L)]n were
prepared from [Cu2(fen)4(dmf)2]2H2O (1) [dmf¼N,N0-dimethylformamide; L¼4,40-bipyridine
(2), pyrazine (3), and 2,5-dimethylpyrazine (4)]. The new complexes were characterized by
chemical analysis, spectroscopic, and thermogravimetric techniques. Antioxidant properties of
chemical analysis, spectroscopic, and thermogravimetric techniques. Antioxidant properties of
chemical analysis, spectroscopic, and thermogravimetric techniques. Antioxidant properties of
(2), pyrazine (3), and 2,5-dimethylpyrazine (4)]. The new complexes were characterized by
chemical analysis, spectroscopic, and thermogravimetric techniques. Antioxidant properties of
chemical analysis, spectroscopic, and thermogravimetric techniques. Antioxidant properties of
chemical analysis, spectroscopic, and thermogravimetric techniques. Antioxidant properties of
(2), pyrazine (3), and 2,5-dimethylpyrazine (4)]. The new complexes were characterized by
chemical analysis, spectroscopic, and thermogravimetric techniques. Antioxidant properties of
chemical analysis, spectroscopic, and thermogravimetric techniques. Antioxidant properties of
chemical analysis, spectroscopic, and thermogravimetric techniques. Antioxidant properties of
2(fen)4(dmf)2]2H2O (1) [dmf¼N,N0-dimethylformamide; L¼4,40-bipyridine
(2), pyrazine (3), and 2,5-dimethylpyrazine (4)]. The new complexes were characterized by
chemical analysis, spectroscopic, and thermogravimetric techniques. Antioxidant properties of
chemical analysis, spectroscopic, and thermogravimetric techniques. Antioxidant properties of
chemical analysis, spectroscopic, and thermogravimetric techniques. Antioxidant properties of
2), pyrazine (3), and 2,5-dimethylpyrazine (4)]. The new complexes were characterized by
chemical analysis, spectroscopic, and thermogravimetric techniques. Antioxidant properties of
14 were evaluated for superoxide-dismutase-mimic activity employing the XTT method.
Complex 2 presented the highest antioxidant activity (IC50¼0.260 mmol L1). Anti-inflammatory
properties of 2 were evaluated employing carrageenan-induced paw edema in mice,
revealing that the Fenoprofencopper(II) complex containing 4,40-bipyridine does not present
enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen
calcium salt.
Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3-
enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen
calcium salt.
Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3-
enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen
calcium salt.
Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3-
revealing that the Fenoprofencopper(II) complex containing 4,40-bipyridine does not present
enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen
calcium salt.
Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3-
enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen
calcium salt.
Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3-
enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen
calcium salt.
Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3-
revealing that the Fenoprofencopper(II) complex containing 4,40-bipyridine does not present
enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen
calcium salt.
Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3-
enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen
calcium salt.
Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3-
enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen
calcium salt.
Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3-
properties of 2 were evaluated employing carrageenan-induced paw edema in mice,
revealing that the Fenoprofencopper(II) complex containing 4,40-bipyridine does not present
enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen
calcium salt.
Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3-
enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen
calcium salt.
Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3-
enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen
calcium salt.
Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3-
revealing that the Fenoprofencopper(II) complex containing 4,40-bipyridine does not present
enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen
calcium salt.
Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3-
enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen
calcium salt.
Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3-
enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen
calcium salt.
Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3-
revealing that the Fenoprofencopper(II) complex containing 4,40-bipyridine does not present
enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen
calcium salt.
Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3-
enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen
calcium salt.
Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3-
enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen
calcium salt.
Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3-
properties of 2 were evaluated employing carrageenan-induced paw edema in mice,
revealing that the Fenoprofencopper(II) complex containing 4,40-bipyridine does not present
enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen
calcium salt.
Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3-
enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen
calcium salt.
Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3-
enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen
calcium salt.
Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3-
revealing that the Fenoprofencopper(II) complex containing 4,40-bipyridine does not present
enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen
calcium salt.
Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3-
enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen
calcium salt.
Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3-
enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen
calcium salt.
Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3-
revealing that the Fenoprofencopper(II) complex containing 4,40-bipyridine does not present
enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen
calcium salt.
Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3-
enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen
calcium salt.
Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3-
enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen
calcium salt.
Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3-
Complex 2 presented the highest antioxidant activity (IC50¼0.260 mmol L1). Anti-inflammatory
properties of 2 were evaluated employing carrageenan-induced paw edema in mice,
revealing that the Fenoprofencopper(II) complex containing 4,40-bipyridine does not present
enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen
calcium salt.
Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3-
enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen
calcium salt.
Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3-
enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen
calcium salt.
Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3-
revealing that the Fenoprofencopper(II) complex containing 4,40-bipyridine does not present
enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen
calcium salt.
Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3-
enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen
calcium salt.
Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3-
enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen
calcium salt.
Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3-
revealing that the Fenoprofencopper(II) complex containing 4,40-bipyridine does not present
enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen
calcium salt.
Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3-
enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen
calcium salt.
Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3-
enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen
calcium salt.
Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3-
properties of 2 were evaluated employing carrageenan-induced paw edema in mice,
revealing that the Fenoprofencopper(II) complex containing 4,40-bipyridine does not present
enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen
calcium salt.
Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3-
enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen
calcium salt.
Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3-
enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen
calcium salt.
Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3-
revealing that the Fenoprofencopper(II) complex containing 4,40-bipyridine does not present
enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen
calcium salt.
Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3-
enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen
calcium salt.
Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3-
enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen
calcium salt.
Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3-
revealing that the Fenoprofencopper(II) complex containing 4,40-bipyridine does not present
enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen
calcium salt.
Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3-
enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen
calcium salt.
Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3-
enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen
calcium salt.
Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3-
properties of 2 were evaluated employing carrageenan-induced paw edema in mice,
revealing that the Fenoprofencopper(II) complex containing 4,40-bipyridine does not present
enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen
calcium salt.
Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3-
enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen
calcium salt.
Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3-
enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen
calcium salt.
Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3-
revealing that the Fenoprofencopper(II) complex containing 4,40-bipyridine does not present
enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen
calcium salt.
Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3-
enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen
calcium salt.
Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3-
enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen
calcium salt.
Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3-
revealing that the Fenoprofencopper(II) complex containing 4,40-bipyridine does not present
enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen
calcium salt.
Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3-
enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen
calcium salt.
Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3-
enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen
calcium salt.
Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3-
Complex 2 presented the highest antioxidant activity (IC50¼0.260 mmol L1). Anti-inflammatory
properties of 2 were evaluated employing carrageenan-induced paw edema in mice,
revealing that the Fenoprofencopper(II) complex containing 4,40-bipyridine does not present
enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen
calcium salt.
Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3-
enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen
calcium salt.
Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3-
enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen
calcium salt.
Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3-
revealing that the Fenoprofencopper(II) complex containing 4,40-bipyridine does not present
enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen
calcium salt.
Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3-
enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen
calcium salt.
Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3-
enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen
calcium salt.
Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3-
revealing that the Fenoprofencopper(II) complex containing 4,40-bipyridine does not present
enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen
calcium salt.
Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3-
enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen
calcium salt.
Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3-
enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen
calcium salt.
Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3-
properties of 2 were evaluated employing carrageenan-induced paw edema in mice,
revealing that the Fenoprofencopper(II) complex containing 4,40-bipyridine does not present
enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen
calcium salt.
Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3-
enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen
calcium salt.
Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3-
enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen
calcium salt.
Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3-
revealing that the Fenoprofencopper(II) complex containing 4,40-bipyridine does not present
enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen
calcium salt.
Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3-
enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen
calcium salt.
Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3-
enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen
calcium salt.
Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3-
revealing that the Fenoprofencopper(II) complex containing 4,40-bipyridine does not present
enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen
calcium salt.
Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3-
enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen
calcium salt.
Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3-
enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen
calcium salt.
Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3-
properties of 2 were evaluated employing carrageenan-induced paw edema in mice,
revealing that the Fenoprofencopper(II) complex containing 4,40-bipyridine does not present
enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen
calcium salt.
Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3-
enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen
calcium salt.
Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3-
enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen
calcium salt.
Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3-
revealing that the Fenoprofencopper(II) complex containing 4,40-bipyridine does not present
enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen
calcium salt.
Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3-
enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen
calcium salt.
Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3-
enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen
calcium salt.
Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3-
revealing that the Fenoprofencopper(II) complex containing 4,40-bipyridine does not present
enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen
calcium salt.
Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3-
enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen
calcium salt.
Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3-
enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen
calcium salt.
Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3-
were evaluated for superoxide-dismutase-mimic activity employing the XTT method.
Complex 2 presented the highest antioxidant activity (IC50¼0.260 mmol L1). Anti-inflammatory
properties of 2 were evaluated employing carrageenan-induced paw edema in mice,
revealing that the Fenoprofencopper(II) complex containing 4,40-bipyridine does not present
enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen
calcium salt.
Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3-
enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen
calcium salt.
Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3-
enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen
calcium salt.
Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3-
revealing that the Fenoprofencopper(II) complex containing 4,40-bipyridine does not present
enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen
calcium salt.
Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3-
enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen
calcium salt.
Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3-
enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen
calcium salt.
Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3-
revealing that the Fenoprofencopper(II) complex containing 4,40-bipyridine does not present
enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen
calcium salt.
Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3-
enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen
calcium salt.
Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3-
enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen
calcium salt.
Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3-
properties of 2 were evaluated employing carrageenan-induced paw edema in mice,
revealing that the Fenoprofencopper(II) complex containing 4,40-bipyridine does not present
enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen
calcium salt.
Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3-
enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen
calcium salt.
Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3-
enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen
calcium salt.
Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3-
revealing that the Fenoprofencopper(II) complex containing 4,40-bipyridine does not present
enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen
calcium salt.
Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3-
enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen
calcium salt.
Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3-
enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen
calcium salt.
Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3-
revealing that the Fenoprofencopper(II) complex containing 4,40-bipyridine does not present
enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen
calcium salt.
Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3-
enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen
calcium salt.
Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3-
enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen
calcium salt.
Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3-
properties of 2 were evaluated employing carrageenan-induced paw edema in mice,
revealing that the Fenoprofencopper(II) complex containing 4,40-bipyridine does not present
enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen
calcium salt.
Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3-
enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen
calcium salt.
Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3-
enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen
calcium salt.
Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3-
revealing that the Fenoprofencopper(II) complex containing 4,40-bipyridine does not present
enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen
calcium salt.
Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3-
enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen
calcium salt.
Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3-
enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen
calcium salt.
Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3-
revealing that the Fenoprofencopper(II) complex containing 4,40-bipyridine does not present
enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen
calcium salt.
Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3-
enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen
calcium salt.
Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3-
enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen
calcium salt.
Three dinuclear copper(II